tert-butyl (2S,4S)-4-methyl-2-[6-[7-[7-(trifluoromethylsulfonyloxy)spiro[1,3-dihydroindene-2,1'-cyclopentane]-4-yl]spiro[1,3-dihydroindene-2,1'-cyclopentane]-4-yl]-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: tert-butyl (2S,4S)-4-methyl-2-[6-[7-[7-(trifluoromethylsulfonyloxy)spiro[1,3-dihydroindene-2,1'-cyclopentane]-4-yl]spiro[1,3-dihydroindene-2,1'-cyclopentane]-4-yl]-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate
• 化学式: C₄₄H₅₀F₃N₃O₅S
• 分子量: 789.9
• InChiKey: GIHBRUVVOOLIGA-UGOHAPBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.9
• 重原子数：
  56
• 可旋转键数：
  7
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS DE TYPE NOYAU SPIRO UTILISABLES EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C, COMPOSITIONS PHARMACEUTIQUES EN CONTENANT ET LEURS UTILISATIONS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014082381A1

  公开（公告）日：2014-06-05

  Provided herein are spiro ring compounds, pharmaceutical compositions and uses in medicine thereof. The compounds having formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions comprising the spiro ring compounds and the use of the compound and/or the pharmaceutical composition thereof for inhibiting at least one of HCV replication process and HCV viral protein function, and for preventing, managing, treating or lessening the severity of HCV infection or a HCV disorder in a patient. (I)